Porton Pharma Solutions Ltd(300363) the performance forecast for 2021 was released on the evening of January 16. The company expects to achieve an operating revenue of 3.004 billion yuan – 3.108 billion yuan in 2021, with a year-on-year increase of 45% – 50%; The net profit attributable to the shareholders of the listed company is expected to be RMB 500 million-532 million, with a year-on-year increase of 54% – 64%; It is estimated that the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses is RMB 519 million-548 million, with a year-on-year increase of 80% – 90%.
For the reasons for performance changes, the announcement shows that in 2021, under the background of the stable growth of global pharmaceutical R & D pipeline and the continuous increase of pharmaceutical R & D and production outsourcing trend, the company continues to expand and enrich product pipeline, continuously improve technical capacity, product delivery capacity and order acquisition capacity, and is expected to achieve an increase of 45% – 50% in operating revenue over the same period of last year. At the same time, with the further improvement of the company’s capacity utilization and operation efficiency and the further optimization of product structure, the company’s profitability has been continuously improved.
In addition, in 2021, the two new business segments of the company’s preparation cdmo (contract R & D and production business organization) and gene cell therapy cdmo continued to “build capacity, build reputation and expand the market”, which was still in the loss stage as a whole, reducing the net profit attributable to shareholders of Listed Companies in the company’s consolidated statements by about 100 million yuan.
